美国 · SEC FORM 4
Altimmune, Inc.
ALT · Nasdaq · CIK 0001326190 · Healthcare · Biotechnology
内部人信号
1 位买方 · 1 条买入交易行 · $44.2K 买入总额
为什么有这个信号?
评分构成
每条进度条表示其对当前分数的贡献;权重和公式保持不变。
哪些因素限制了当前分数?
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ 角色得分低 · 买入者中职位最高的是:President and CEO(CEO、董事长和持股 10% 以上的股东得分最低)
- ⚠ Purchase activity is becoming less recent
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后,不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: President and CEO. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 38.5
- 38.5
- 38.4
- 38.2
- 38.1
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息,不影响内部人信号。
价格表现
- 1M
- -20.7%
- 3M
- -12.7%
- 6M
- -19.4%
- 12M
- -33.6%
波动率与流动性
- 波动率
- 82.0%
- Beta
- —
- 平均每日成交额
- USD 11.1M
估值
- 市值
- USD 507.7M
- P/E
- —
基本面
- 利润率
- —
- ROE
- -39.2%
- 细分行业
- Biotechnology
市场数据
价格数据截至:2026-10-11 · 价格来源:OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件:市值, ROE · 财年截止日:2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期:2026-08-07 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 46,079,911
- 上期报告
- 51,749,756
- 日均成交量
- 4,373,581
- 回补天数
- 10.5
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-13 | Durso Jerome Benedict | 买入 (P) | Common Stock, par value $0.0001 | 15,000 | USD 2.95 | USD 44,250 | SEC 申报 ↗ |
| 2026-04-06 | GILL JOHN | 买入 (P) | Common Stock, par value $0.0001 | 9,200 | USD 3.41 | USD 31,372 | SEC 申报 ↗ |
| 2026-04-01 | WEAVER GREGORY L | 买入 (P) | Common Stock, par value $0.0001 | 10,000 | USD 3.15 | USD 31,500 | SEC 申报 ↗ |
| 2026-04-01 | Durso Jerome Benedict | 买入 (P) | Common Stock, par value $0.0001 | 15,000 | USD 3.14 | USD 47,100 | SEC 申报 ↗ |
| 2026-03-06 | WEAVER GREGORY L | 买入 (P) | Common Stock, par value $0.0001 | 5,000 | USD 3.54 | USD 17,700 | SEC 申报 ↗ |
| 2026-03-06 | Durso Jerome Benedict | 买入 (P) | Common Stock, par value $0.0001 | 20,000 | USD 3.54 | USD 70,800 | SEC 申报 ↗ |
| 2026-01-08 | Pisano Wayne | 买入 (P) | Common Stock, par value $0.0001 | 5,000 | USD 4.08 | USD 20,400 | SEC 申报 ↗ |
| 2026-01-05 | Sohn Catherine A. | 买入 (P) | Common Stock, par value $0.0001 | 500 | USD 4.24 | USD 2,120 | SEC 申报 ↗ |
| 2025-12-29 | Jorkasky Diane | 买入 (P) | Common Stock, par value $0.0001 | 527 | USD 3.80 | USD 2,003 | SEC 申报 ↗ |
| 2025-12-23 | GILL JOHN | 买入 (P) | Common Stock, par value $0.0001 | 12,500 | USD 4.10 | USD 51,250 | SEC 申报 ↗ |
| 2025-12-22 | Durso Jerome Benedict | 买入 (P) | Common Stock, par value $0.0001 | 12,500 | USD 4.13 | USD 51,625 | SEC 申报 ↗ |
| 2025-03-17 | Sohn Catherine A. | 买入 (P) | Common Stock, par value $0.0001 | 1,000 | USD 5.78 | USD 5,780 | SEC 申报 ↗ |
| 2025-03-13 | WEAVER GREGORY L | 买入 (P) | Common Stock, par value $0.0001 | 10,000 | USD 5.20 | USD 52,000 | SEC 申报 ↗ |
| 2023-08-15 | Drutz David | 买入 (P) | Common Stock, par value $0.0001 | 300 | USD 2.88 | USD 864 | SEC 申报 ↗ |
| 2023-03-24 | Eisenstadt Richard I | 买入 (P) | Common Stock, par value $0.0001 | 10,000 | USD 4.31 | USD 43,100 | SEC 申报 ↗ |
Form 4 申报证据
44 transaction lines in the latest 365-day window; 262 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | WEAVER GREGORY L | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 14,475 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-01 | WEAVER GREGORY L | 代扣税 (F) | Common Stock, par value $0.0001 | 4,379 | USD 2.76 | USD 12,086 | SEC 申报 ↗ |
| 2026-10-01 | Arbet-Engels Christophe | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 37,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | WEAVER GREGORY L | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 14,475 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-01 | WEAVER GREGORY L | 代扣税 (F) | Common Stock, par value $0.0001 | 4,379 | USD 2.76 | USD 12,086 | SEC 申报 ↗ |
| 2026-10-01 | Arbet-Engels Christophe | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 37,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-01 | Arbet-Engels Christophe | 代扣税 (F) | Common Stock, par value $0.0001 | 12,679 | USD 2.76 | USD 34,994 | SEC 申报 ↗ |
| 2026-09-16 | Richardson Linda M | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 24,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-16 | Richardson Linda M | 代扣税 (F) | Common Stock, par value $0.0001 | 6,826 | USD 3.24 | USD 22,116 | SEC 申报 ↗ |
| 2026-08-13 | Durso Jerome Benedict | 买入 (P) | Common Stock, par value $0.0001 | 15,000 | USD 2.95 | USD 44,250 | SEC 申报 ↗ |
| 2026-07-31 | WEAVER GREGORY L | 奖励/授予 (A) | Common Stock, par value $0.0001 | 1,753 | USD 2.41 | USD 4,225 | SEC 申报 ↗ |
| 2026-07-31 | Roberts M Scot | 奖励/授予 (A) | Common Stock, par value $0.0001 | 875 | USD 2.41 | USD 2,109 | SEC 申报 ↗ |
| 2026-04-06 | GILL JOHN | 买入 (P) | Common Stock, par value $0.0001 | 9,200 | USD 3.41 | USD 31,372 | SEC 申报 ↗ |
| 2026-04-01 | WEAVER GREGORY L | 买入 (P) | Common Stock, par value $0.0001 | 10,000 | USD 3.15 | USD 31,500 | SEC 申报 ↗ |
| 2026-04-01 | Durso Jerome Benedict | 买入 (P) | Common Stock, par value $0.0001 | 15,000 | USD 3.14 | USD 47,100 | SEC 申报 ↗ |
| 2026-03-06 | WEAVER GREGORY L | 买入 (P) | Common Stock, par value $0.0001 | 5,000 | USD 3.54 | USD 17,700 | SEC 申报 ↗ |
| 2026-03-06 | Durso Jerome Benedict | 买入 (P) | Common Stock, par value $0.0001 | 20,000 | USD 3.54 | USD 70,800 | SEC 申报 ↗ |
| 2026-02-02 | Roberts M Scot | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 7,775 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-02 | Roberts M Scot | 代扣税 (F) | Common Stock, par value $0.0001 | 2,329 | USD 5.55 | USD 12,926 | SEC 申报 ↗ |
| 2026-01-31 | Roberts M Scot | 奖励/授予 (A) | Common Stock, par value $0.0001 | 5,567 | USD 3.07 | USD 17,091 | SEC 申报 ↗ |
| 2026-01-31 | Jordt Raymond M | 奖励/授予 (A) | Common Stock, par value $0.0001 | 4,571 | USD 3.07 | USD 14,033 | SEC 申报 ↗ |
| 2026-01-31 | Garg Vipin K | 奖励/授予 (A) | Common Stock, par value $0.0001 | 6,926 | USD 3.07 | USD 21,263 | SEC 申报 ↗ |
| 2026-01-30 | Roberts M Scot | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 9,275 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Roberts M Scot | 代扣税 (F) | Common Stock, par value $0.0001 | 2,859 | USD 5.60 | USD 16,010 | SEC 申报 ↗ |
| 2026-01-30 | Garg Vipin K | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 26,775 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Garg Vipin K | 代扣税 (F) | Common Stock, par value $0.0001 | 11,632 | USD 5.60 | USD 65,139 | SEC 申报 ↗ |
| 2026-01-27 | Roberts M Scot | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 15,850 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-27 | Roberts M Scot | 代扣税 (F) | Common Stock, par value $0.0001 | 4,748 | USD 6.18 | USD 29,343 | SEC 申报 ↗ |
| 2026-01-27 | Jordt Raymond M | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 15,850 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-27 | Jordt Raymond M | 代扣税 (F) | Common Stock, par value $0.0001 | 4,229 | USD 6.18 | USD 26,135 | SEC 申报 ↗ |
| 2026-01-27 | Garg Vipin K | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 41,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-27 | Garg Vipin K | 代扣税 (F) | Common Stock, par value $0.0001 | 17,898 | USD 6.18 | USD 110,610 | SEC 申报 ↗ |
| 2026-01-25 | Roberts M Scot | 期权行权/转换 (M) | Common Stock, par value $0.0001 | 14,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ALT |
| CIK | 0001326190 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 262 transaction lines from 2020-01-30 to 2026-10-01 27 P purchase lines · 21 S sale lines · 214 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.